Eyegate Pharmaceuticals Inc.
Eyegate Pharmaceuticals, Inc. was established upon the need for a safer, more efficient method to administer ocular therapeutics. At present, physicians are limited to topical instillations, systemic administrations, intravitreal or periocular injections, and intraocular depots, all of which are associated with deleterious side effects. Eyegate has built a technology platform based on the fundamental principles of Iontophoresis. The Eyegate technology was developed at the Bascom Palmer Eye Institute by ophthalmologists specifically for ocular indications. The applicator was designed to avoid contact with the cornea, minimizing the pain and potential cataract formation due to localized heat production. We take advantage of the large surface area of the sclera allowing the current density to be dispersed thus increasing the tolerated dose of applied current. Molecules as large as 150 kD have been shown to passively traverse the sclera with impressive deposition efficiencies. A safe non-invasive alternative would be welcomed by ophthalmologists and patient advocacy groups alike.Back to list